EyePoint Inc EYPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Trading Information
- Previous Close Price
- $0.32
- Day Range
- $0.31–0.33
- 52-Week Range
- $0.31–19.11
- Bid/Ask
- $0.31 / $0.33
- Shares Outstanding
- 113.78M
- Market Cap
- $26.38M
- Volume/Avg
- 3M / 9M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 214
- Website
- https://www.eyepoint.bio
Valuation
Metric | EYPT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.26 |
Price/Sales | 10.23 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | EYPT |
|---|---|
Quick Ratio | 3.08 |
Current Ratio | 3.30 |
Interest Coverage | — |
Quick Ratio
EYPT
Profitability
Metric | EYPT |
|---|---|
Return on Assets (Normalized) | −120.27% |
Return on Equity (Normalized) | −154.33% |
Return on Invested Capital (Normalized) | −143.45% |
Return on Assets
EYPT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<c#k$r | LOCK|^XN<w | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|l>CW?vN | LOCK|CV!n | $99B | |||
| Moderna Inc MRNA | LOCK|?@g$jl@ | LOCK|YW# | $90B | |||
| argenx SE ADR ARGX | LOCK|jsP$db | LOCK|<mK | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|^FJbKz$ | LOCK|WC^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%G^sHl? | LOCK|#S!%n | $31B | |||
| Incyte Corp INCY | LOCK|CzzM$# | LOCK|b^ | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|vZ$$?h | LOCK|sq$gp | $22B | |||
| BioNTech SE ADR BNTX | LOCK|T$v#w!> | LOCK|Lp | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&Hgjt&h | LOCK|b# | $16B |
United States